
| Pair Name | Evodiamine, Gemcitabine | ||
| Phytochemical Name | Evodiamine (PubChem CID: 442088 ) | ||
| Anticancer drug Name | Gemcitabine (PubChem CID: 60750 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Evodiamine, Gemcitabine | |||
| Disease Info | [ICD-11: 2B62.Z] | Tongue cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
| Down-regulation | Expression | BCL-xL | hsa598 | |
| Down-regulation | Expression | RELA | hsa5970 | |
| In Vitro Model | CAL-27 | Tongue adenosquamous carcinoma | Homo sapiens (Human) | CVCL_1107 |
| Tca8113 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6851 | |
| In Vivo Model | CAL-27 cells (2×10⁶) were injected subcutaneously into the right armpit regions of nude mice. | |||
| Result | The results of this study showed that EVO may inhibit cancer cells by suppressing NF-κB activity, and in combination with GEM, it may increase the chemosensitivity of tongue squamous cancer cells, thereby improving the treatment response. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Evodiamine inactivates NF-κB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. Onco Targets Ther. 2018;12:257-267. Published 2018 Dec 27. doi:10.2147/OTT.S181062 | Click |